Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | April 23, 2019 | April 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 23, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 169,935 |
Ending reported balance
After 2019-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-23 · Exercise / conversion · Acquired 56,000 · Balance 225,935 Row 2 · 2019-04-23 · Sale · Disposed 56,000 · Balance 169,935 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 113,227 |
Reported balance
After 2019-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-23 · Exercise / conversion · Disposed 56,000 · Balance 113,227 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,698 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,698 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 53 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 53 F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019.
F2: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2013 Filed Feb 20, 2013 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 149,600 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-13-003138 · edgar.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,600 Underlying: Common shares · 149,600 shares Expires 2023-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 49,867 on 2/15/2014, 49,866 on 2/15/2015, and 49,867 on 2/15/2016. Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 28,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003138 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,893 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,690 | $0.00 Strike: $31.90 | $0.00 |
DisclosureSEC source: 0001179110-13-001810 · edgar.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 9,690 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,690 | $33.89 | $328,394.10 |
DisclosureSEC source: 0001179110-13-001810 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,093 Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,690 | $31.90 | $309,122.63 |
DisclosureSEC source: 0001179110-13-001810 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2012 Filed Oct 26, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,948 | $0.00 Strike: $60.39 | $0.00 |
DisclosureSEC source: 0001179110-12-015433 · edgar.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,948 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 24, 2012 Filed Oct 26, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $66.00 | $132,000.00 |
DisclosureSEC source: 0001179110-12-015433 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,093 Read SEC document |
| October 24, 2012 Filed Oct 26, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,948 | $66.00 | $392,568.00 |
DisclosureSEC source: 0001179110-12-015433 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,093 Read SEC document |
| October 24, 2012 Filed Oct 26, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,948 | $60.39 | $359,199.72 |
DisclosureSEC source: 0001179110-12-015433 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 9,690 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001179110-12-012176 · edgar.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,690 Underlying: Common shares · 9,690 shares Expires 2013-02-13 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,988 | $0.00 Strike: $53.00 | $0.00 |
DisclosureSEC source: 0001179110-12-012176 · edgar.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,988 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,690 | $66.39 | $643,319.10 |
DisclosureSEC source: 0001179110-12-012176 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,093 Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,988 | $53.00 | $582,364.00 |
DisclosureSEC source: 0001179110-12-012176 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,275 | $0.00 Strike: $50.95 | $0.00 |
DisclosureSEC source: 0001179110-12-011157 · edgar.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,275 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,275 | $64.42 | $146,557.78 |
DisclosureSEC source: 0001179110-12-011157 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,795 Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,275 | $50.95 | $115,911.25 |
DisclosureSEC source: 0001179110-12-011157 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2012 Filed Jun 4, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,100 | $61.21 | $250,961.00 |
DisclosureSEC source: 0001179110-12-009527 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,795 Read SEC document |
| June 01, 2012 Filed Jun 4, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $61.21 | $116,300.90 |
DisclosureSEC source: 0001179110-12-009527 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,895 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 5,948 | $0.00 Strike: $60.39 | $0.00 |
DisclosureSEC source: 0001179110-12-005694 · edgar.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,948 Underlying: Common shares · 5,948 shares Expires 2013-02-13 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,818 | $0.00 Strike: $47.82 | $0.00 |
DisclosureSEC source: 0001179110-12-005694 · edgar.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,818 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,525 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001179110-12-005694 · edgar.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,525 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,948 | $60.39 | $359,199.72 |
DisclosureSEC source: 0001179110-12-005694 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,795 Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,818 | $47.82 | $278,216.76 |
DisclosureSEC source: 0001179110-12-005694 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2012 Filed Mar 23, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,525 | $33.23 | $50,677.89 |
DisclosureSEC source: 0001179110-12-005694 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $56.71 | $11,341.00 |
DisclosureSEC source: 0001179110-12-004085 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,400 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $56.70 | $11,340.10 |
DisclosureSEC source: 0001179110-12-004085 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,600 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 467 | $56.70 | $26,479.37 |
DisclosureSEC source: 0001179110-12-004085 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,800 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 40 | $56.70 | $2,268.08 |
DisclosureSEC source: 0001179110-12-004085 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,267 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,259 | $57.04 | $585,173.36 |
DisclosureSEC source: 0001179110-12-004085 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,307 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 44,000 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003234 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common shares · 44,000 shares Expires 2022-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,667 on 02/17/2013, 14,666 on 02/17/2014, and 14,667 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003234 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,566 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 21,281 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,281 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $54.24 | $43,392.56 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,166 Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $54.24 | $43,392.16 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,966 Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $54.24 | $16,272.03 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,766 Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 19,381 | $54.24 | $1,051,225.44 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,066 Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 21,281 | $53.63 | $1,141,193.63 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2011 Filed Sep 14, 2011 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 450 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-11-013256 · edgar.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common shares · 450 shares Expires 2011-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 12, 2011 Filed Sep 14, 2011 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 450 | $49.87 | $22,442.40 |
DisclosureSEC source: 0001179110-11-013256 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 126 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| September 12, 2011 Filed Sep 14, 2011 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 450 | $44.16 | $19,872.00 |
DisclosureSEC source: 0001179110-11-013256 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $52.92 | $10,584.00 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,166 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,023 | $52.92 | $107,059.18 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,366 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $52.92 | $47,629.80 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,389 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $52.93 | $5,293.00 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,289 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 509 | $52.93 | $26,941.88 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,389 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $52.93 | $10,586.50 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,898 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $52.92 | $10,584.50 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,098 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,725 | $52.95 | $91,340.48 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,298 Read SEC document |
| July 25, 2011 Filed Jul 27, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 143 | $52.95 | $7,572.21 |
DisclosureSEC source: 0001179110-11-011296 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,023 F1 · balance_after: Balance reflects the reporting person's transfer of 43,008 Abbott common shares to his former spouse pursuant to a domestic relations order. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,564 | $47.93 | $74,967.21 |
DisclosureSEC source: 0001179110-11-003910 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,174 F1 · balance_after: Amount is subject to adjustment pursuant to a domestic relations order. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.